Navigation Links
EUCODIS Bioscience Signs Research Agreement With Genencor
Date:5/21/2009

VIENNA, Austria, May 21 /PRNewswire/ -- EUCODIS Bioscience, a company developing, manufacturing, and marketing enzymes and other proteins for the chemical industry, announced today that it has entered into a research agreement with Genencor, a division of Danisco. Under the terms of the agreement, EUCODIS Bioscience will apply its proprietary, patent-protected technology of "in vivo recombination" to the development of an optimized version of an undisclosed enzyme. The Company will generate a library of recombinants of the enzyme, and Genencor will screen the library for clones (enzymes) with desired product profiles.

"We are pleased that Genencor, a leading enzyme manufacturer and one of the largest biotechnology companies worldwide, has chosen EUCODIS Bioscience as a partner", said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "In previous development programs - both for our own portfolio of commercial enzymes and for industrial partners - our technology of in vivo recombination has reliably shown its capacity to generate high-quality libraries of active enzymes with significant improvement of the desired activities in a single cycle of recombination."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visithttp://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD, CEO
    EUCODIS Bioscience
    Brunner Strasse 59
    1230 VIENNA
    AUSTRIA
    +43-1-86634-9241
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
   http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net



'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
2. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
3. Universite de Montreal and Validapro Biosciences Inc. have Signed an Agreement-in-Principle
4. YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
5. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
6. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
7. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
8. Neurocrine Biosciences Reports First Quarter 2009 Results
9. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
10. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
11. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- UCHealth ( Aurora, Colorado ) becomes ... patient management. In addition to optimizing care coordination for ... lung, UCHealth looks to improve provider workflow by decreasing ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, ... Excel spreadsheet, which was extremely arduous and susceptible to ...
(Date:2/16/2017)... 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, ... study showed that aerosolized KL4 surfactant reduced lung ... preclinical animal model. The Company believes that these ... evidence that supports the role of KL4 surfactant ...
(Date:2/15/2017)... ... 15, 2017 , ... Executive search firm, Slone Partners, announces ... Matt is a veteran life sciences and molecular diagnostics executive with extensive ... identifying inherited disease risk in future generations. In his new role, Matt will ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
Breaking Biology Technology:
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
(Date:1/24/2017)... 24, 2017  It sounds simple and harmless—an ... monitors vital signs and alerts parents on their ... saturation level drops. But pediatric experts argue that ... with no evidence of medical benefits, especially to ... aggressively to parents of healthy babies, promising peace ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
Breaking Biology News(10 mins):